Literature DB >> 3240007

Urinary excretion of 6-keto prostaglandin F1 alpha in pre-eclampsia.

M Yamaguchi1, N Mori.   

Abstract

In order to investigate whether urinary excretion of prostaglandins (PG) is involved in the pathophysiology of pre-eclampsia, urinary immunoreactive 6-keto PGF1 alpha and TXB2 were measured in normal and pre-eclamptic women by radio-immunoassay after extraction with Bond Elut column. Urinary levels of 6-keto PGF1 alpha and TXB2 were expressed as ratio of urinary concentration of prostaglandin vs. creatinine (pg prostaglandin/mg creatinine; pg/mg cre.). Urinary excretion in normal pregnant and postpartum women were 211.2 +/- 33.8 and 160.1 +/- 9.1 pg/mg cre., respectively. In the pre-eclamptic group, urinary excretion of 6-keto PGF1 alpha was 105.3 +/- 28.2 pg/mg cre. in pregnancy and 99.0 +/- 12.5 pg/mg cre. in the postpartum period. Urinary excretion of 6-keto PGF1 alpha in the pre-eclamptic group was significantly lower (P less than 0.05) than in normal controls during pregnancy but not in the postpartum period. Urinary excretion of TXB2 was not significantly different between the two groups. The urinary excretion of 6-keto PGF1 alpha was measured before and after the onset of pre-eclampsia in four cases of edema and weight gain of more than 500 g/week (group e), one case of proteinuria of more than 200 mg/dl with edema (group ep) and three cases of pre-eclampsia (group eph). The urinary excretion of 6-keto PGF1 alpha in these eight patients before onset of pre-eclampsia was slightly lower than of normal controls but not significantly so. In group eph, urinary excretion of PG was decreased after the onset of pre-eclampsia. These results provide further evidence of the involvement of PG in the pathophysiology of pre-eclampsia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3240007     DOI: 10.1007/bf00931397

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  15 in total

Review 1.  Effect of prostaglandins on renal salt and water excretion.

Authors:  K H Raymond; M D Lifschitz
Journal:  Am J Med       Date:  1986-01-17       Impact factor: 4.965

2.  Effect of prostacyclin on renal kallikrein release in man.

Authors:  A Pierucci; B M Simonetti; G Ciabattoni; F Taggi; S Morabito; S Vastano; F Pugliese
Journal:  Eur J Clin Invest       Date:  1986-06       Impact factor: 4.686

3.  A clinical test useful for predicting the development of acute hypertension in pregnancy.

Authors:  N F Gant; S Chand; R J Worley; P J Whalley; U D Crosby; P C MacDonald
Journal:  Am J Obstet Gynecol       Date:  1974-09       Impact factor: 8.661

4.  Renin, angiotensin II, aldosterone, catecholamines, prostaglandins and vasopressin. The importance of pressor and depressor factors for hypertension in pregnancy.

Authors:  E B Pedersen; C Aalkjaer; N J Christensen; P Christensen; H Danielsen; P Johannesen; H J Kornerup; P P Leyssac; M Mulvany; A B Rasmussen
Journal:  Scand J Clin Lab Invest Suppl       Date:  1984

5.  Renal prostaglandins E2 and F2 alpha in normal pregnancy and in pregnancy with hypertension.

Authors:  S Kovatz; M Rathaus; N B Aderet; J Bernheim
Journal:  Proc Eur Dial Transplant Assoc       Date:  1981

6.  Hypertension in pregnancy. Prostaglandins, kinins and kallikrein.

Authors:  B E Karlberg; K Wichman
Journal:  Scand J Clin Lab Invest Suppl       Date:  1984

7.  Urinary excretion of arterial blood prostaglandins and thromboxanes in man.

Authors:  R D Zipser; K Martin
Journal:  Am J Physiol       Date:  1982-03

8.  Metabolism of prostacyclin in rat.

Authors:  F F Sun; B M Taylor
Journal:  Biochemistry       Date:  1978-09-19       Impact factor: 3.162

9.  Endogenous prostacyclin synthesis is decreased during activation of the renin-angiotensin system in man.

Authors:  M L Watson; R P Goodman; J R Gill; R A Branch; A R Brash; G A Fitzgerald
Journal:  J Clin Endocrinol Metab       Date:  1984-02       Impact factor: 5.958

10.  Estimated rate of prostacyclin secretion into the circulation of normal man.

Authors:  G A FitzGerald; A R Brash; P Falardeau; J A Oates
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.